Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 263-268

  Bhatt, Deepak L ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; THROMBOSIS;

ARTERIOSCLEROSIS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS; THROMBOSIS; TICLOPIDINE;

EID: 4143064763     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.028     Document Type: Article

References (45)

1. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases, I general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 104:2001;2746-2753
2. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases, II variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 104:2001;2855-2864
3. Smith S.C. Jr, Greenland P., Grundy S.M. AHA Conference Proceedings. Prevention conference V beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation. 101:2000;111-116
4. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234
5. Bhatt D.L., Topol E.J. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am. 84:2000;163-179
6. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002 ;324:71-86
7. Sanmuganathan P.S., Ghahramani P., Jackson P.R., et al. Aspirin for primary prevention of coronary heart disease safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 85:2001;265-271
8. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002 ;136:157-60
9. Hayden M., Pignone M., Phillips C., et al. Aspirin for the primary prevention of cardiovascular events a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 136:2002;161-172
10. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 335:1996;1001-1009
11. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials. JAMA. 282:1999;2340-2346
12. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153
13. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 105:2002;691-696
14. Chan A.W., Bhatt D.L., Chew D.P., et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 107:2003;1750-1756
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339
16. Bhatt D.L., Hirsch A.T., Ringleb P.A., et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J. 140:2000;67-73
17. Bhatt D., Marso S., Hirsch A., et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 90:2002;625-628
18. Bhatt D.L., Chew D.P., Hirsch A.T., et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 103:2001;363-368
19. Ringleb P.A., Bhatt D.L., Hirsch A.T., et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 35:2004;528-532
20. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502
21. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention the PCI-CURE study. Lancet. 358:2001;527-533
22. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 108:2003;1682-1687
23. Topol E.J., Easton D., Harrington R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 108:2003;399-406
24. Cannon C.P., Battler A., Brindis R.G., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 38:2001;2114-2130
25. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
26. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial phase I hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11
27. Bhatt D.L., Topol E.J. Need to test the arterial inflammation hypothesis. Circulation. 106:2002;136-140
28. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979
29. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 88:2001;672-674
30. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2:2003;15-28
31. Hermann A., Rauch B.H., Braun M., et al. Platelet CD40 ligand (CD40L) subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 12:2001;74-82
32. Quinn M, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004;93:679-84
33. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science. 291:2001;1304-1351
34. Topol E.J., McCarthy J., Gabriel S., et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 104:2001;2641-2644
35. Wang L., Fan C., Topol S.E., et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 302:2003;1578-1581
36. White H.D., Simes R.J., Anderson N.E., et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 343:2000;317-326
37. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial. Lancet 2002; 360:7-22
38. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 339:1998;1665-1671
39. Bhatt D.L., Bertrand M.E., Berger P.B., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 39:2002;9-14
40. Bhatt D.L., Kapadia S.R., Bajzer C.T., et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol. 13:2001;767-771
41. Bhatt D.L., Kapadia S.R., Yadav J.S., et al. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. Cerebrovasc Dis. 10:(Suppl S5):2000;34-40
42. Steinhubl S.R., Berger P.B., Mann J.T. III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial. JAMA. 288:2002;2411-2420
43. Bhatt D.L., Foody J.M., Hirsch A.T., et al. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol. 35:(Suppl A):2000;326
44. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 325:1991;1261-1266
45. Taylor D.W., Barnett H.J., Haynes R.B., et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 353:1999;2179-2184